Spots Global Cancer Trial Database for kidney
Every month we try and update this database with for kidney cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | NCT02793128 | Carcinoma, Tran... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma | NCT01606345 | Urothelial Carc... | Valrubicin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT01551030 | Metastatic Tran... | Buparlisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| TroVax Renal Immunotherapy Survival Trial | NCT00397345 | Clear Cell Rena... | Trovax Placebo Standard of car... | 18 Years - | Oxford BioMedica | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) | NCT01453595 | Renal Cancer | BEZ235 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC | NCT01791387 | Clear Cell Rena... | Dovitinib | 18 Years - | Auckland District Health Board | |
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | NCT00095186 | Carcinoma, Rena... | Recombinant Hum... | 18 Years - | Agennix | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma | NCT00277017 | Kidney Cancer | 5-Flourouracil,... | - | New Mexico Cancer Care Alliance | |
| Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | NCT03528057 | Robotic-Assiste... Hemostatic Agen... Renal Malignant... | Hemostat | 18 Years - 89 Years | Northwestern University | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | NCT01606787 | Renal Cancer | mannitol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | NCT03528057 | Robotic-Assiste... Hemostatic Agen... Renal Malignant... | Hemostat | 18 Years - 89 Years | Northwestern University | |
| Hepatic and Renal Thermography Using Magnetic Resonance Imaging | NCT01197820 | Liver Tumors Kidney Carcinom... | MRI | 18 Years - | University Hospital, Bordeaux | |
| An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | NCT00992121 | Carcinoma, Rena... | Bevacizumab Pazopanib 2 wee... Pazopanib 3 wee... | 18 Years - | GlaxoSmithKline | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | NCT02307474 | Clear Cell Rena... Renal Cell Carc... | Stereotactic Ra... Pazopanib Hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | NCT03050060 | Metastatic Kidn... Recurrent Lung ... Stage IV Cutane... Stage IV Renal ... Stage IV Lung N... | Atezolizumab Hypofractionate... Laboratory Biom... Nelfinavir Mesy... Nivolumab Pembrolizumab | 18 Years - | University of Washington | |
| A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | NCT01865747 | Renal Cell Carc... | Cabozantinib ta... Everolimus (Afi... | 18 Years - | Exelixis | |
| Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer | NCT00033137 | Kidney Neoplasm... Kidney Cancer Pneumothorax FLCN Protein, H... | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| Percutaneous Renal Tumor Cryoablation Followed by Biopsy | NCT01012427 | Renal Cancer | percutaneous cr... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute | |
| Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | NCT00001703 | Renal Cell Carc... | incomplete Freu... von Hippel-Lind... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | NCT00422344 | Renal Cell Carc... Kidney Cancer | RAD001, Sunitin... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation | NCT04968990 | Wilms Tumor | Proton Beam Rad... DD-4A Chemother... Complete Surgic... Surgical Resect... Partial Nephrec... | - | St. Jude Children's Research Hospital | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | NCT00095186 | Carcinoma, Rena... | Recombinant Hum... | 18 Years - | Agennix | |
| Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation | NCT04968990 | Wilms Tumor | Proton Beam Rad... DD-4A Chemother... Complete Surgic... Surgical Resect... Partial Nephrec... | - | St. Jude Children's Research Hospital | |
| MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers | NCT06126159 | Kidney Neoplasm... | multiparametric... | 20 Years - | Chang Gung Memorial Hospital | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | NCT00561912 | Renal Cell Carc... | Decitabine Interferon Alfa... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03170960 | Urothelial Carc... Renal Cell Carc... Non-Small Cell ... Castration-resi... Triple Negative... Ovarian Cancer Endometrial Can... Hepatocellular ... Gastric Cancer Gastroesophagea... Colorectal Canc... Head and Neck C... Differentiated ... Lower Esophagea... | cabozantinib atezolizumab cabozantinib cabozantinib | 18 Years - | Exelixis | |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | NCT03633110 | Cutaneous Melan... Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... | GEN-009 Adjuvan... Nivolumab Pembrolizumab | 18 Years - | Genocea Biosciences, Inc. | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma | NCT00554515 | Metastatic Rena... | HD IL2 | 18 Years - 80 Years | Beth Israel Deaconess Medical Center | |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) | NCT01453595 | Renal Cancer | BEZ235 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment | NCT01888198 | Renal Cancer | (EORTC QLQ-C30)... EuroQol EQ-5D 7... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment | NCT02301117 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | NCT02793128 | Carcinoma, Tran... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Diagnostic Value of Sonazoid Contrast-enhanced Ultrasound in Renal Tumors | NCT04626115 | Contrast Enhanc... | 18 Years - 85 Years | Chinese PLA General Hospital | ||
| Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | NCT01399918 | Renal Cell Carc... | everolimus and ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib | NCT03129724 | Kidney Neoplasm... | 18 Years - | University Hospital, Strasbourg, France | ||
| A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases | NCT01676428 | Cancer | Radiotherapy | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment | NCT01888198 | Renal Cancer | (EORTC QLQ-C30)... EuroQol EQ-5D 7... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Epione® Post-Market Clinical Follow-up Study | NCT05529979 | Cancer Abdomen | EPIONE® CT-Guid... | 18 Years - | Quantum Surgical | |
| Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma | NCT01173445 | Renal Cell Carc... | 18 Years - | University of Kansas Medical Center | ||
| Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma | NCT00277017 | Kidney Cancer | 5-Flourouracil,... | - | New Mexico Cancer Care Alliance | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) | NCT01122615 | Renal Cell Canc... Kidney Cancer | Sunitinib Temsirolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of UGN-101 in Recurrent Patients | NCT04006691 | Carcinoma Transitional Ce... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Renal Hypothermia During Partial Nephrectomy | NCT01529658 | Renal Impairmen... Kidney Diseases Urologic Diseas... Cancer Hypothermia Kidney Cancer | Renal hypotherm... | 18 Years - | Ottawa Hospital Research Institute | |
| Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients | NCT00129961 | Skin Neoplasms Kidney Transpla... | sirolimus cyclosporine or... | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| DWI in the Diagnosis of Histological Types of Nephroblastoma in Children | NCT04814758 | Nephroblastoma ... | MRI DWI sequenc... | 6 Days - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | NCT00422344 | Renal Cell Carc... Kidney Cancer | RAD001, Sunitin... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| The Effect of Pneumoperitoneum (Raised Pressure in the Peritoneal Cavity) During Robotic Kidney/Prostate Cancer Surgery. | NCT04755452 | Acute Kidney In... Pneumoperitoneu... Kidney | Low intra-abdom... High (standard)... | 18 Years - 85 Years | Aalborg University Hospital | |
| DWI in the Diagnosis of Histological Types of Nephroblastoma in Children | NCT04814758 | Nephroblastoma ... | MRI DWI sequenc... | 6 Days - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Ph II Study of Perifosine for Patients With Carcinoma of the Kidney | NCT00498966 | Kidney Cancer | Perifosine | 18 Years - | AEterna Zentaris | |
| Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | NCT01606787 | Renal Cancer | mannitol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
